Tenaya Therapeutics, Inc. (TNYA): Nasdaq/NYSE listing notice — Tenaya receives Nasdaq bid price deficiency notice; 180-day cure period to July 27, 2026

Tenaya Therapeutics, Inc.

Nasdaq notified Tenaya on Jan 28, 2026 that stock failed to meet $1.00 minimum bid price for 30 consecutive business days through Jan 27, 2026.
Company has 180 days, until July 27, 2026, to regain compliance by maintaining $1.00 closing bid for 10 consecutive business days.
If not cured, Tenaya may transfer to Nasdaq Capital Market for second 180-day compliance period, subject to eligibility and application.
Board approved increase in Inducement Plan shares by 2,161,000 to a total of 3,361,000 shares for new-hire equity grants.
Inducement Plan amendment effective Jan 26, 2026; awards limited to new employees as material inducement under Nasdaq rules.

item 3.01 item 5.02 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Listing & Compliance Notices SEC 8-K Item 3.01 confidence 0.9

Tenaya Therapeutics, Inc. received a nasdaq deficiency notice notice regarding minimum bid price (rules 5450(a)(1)).

Exchange: nasdaq
Notice: deficiency notice
Deficiency: minimum bid price
Rules: 5450(a)(1)

Exact text from the filing

January 28, 2026, Tenaya Therapeutics, Inc. (the “Company”) received a letter from the Listing Qualifications Staff (the “Staff”) of The Nasdaq Stock Market LLC (“Nasdaq”) indicating that, based upon the closing bid price of shares of the Company’s common stock for the 30 consecutive business day period between December 12, 2025, through January 27, 2026, the Company did not meet the minimum bid price of $1.00 per share required for continued listing on the Nasdaq Global Select Market pursuant to Nasdaq Listing Rule 5450(a)(1). The letter also indicated that the Company will be provided with a

View on SEC.gov

5 listing & compliance notices filed in the last 30 days. Browse all listing & compliance notices →

Tenaya Therapeutics, Inc. filing history →

Source: SEC EDGAR

accession 0001193125-26-032017

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.